Core Viewpoint - Beida Pharmaceutical (000788.SZ) has received the Drug Registration Certificate from the National Medical Products Administration for Apremilast tablets, indicating a significant advancement in its product pipeline for treating moderate to severe plaque psoriasis in adults [1] Group 1: Product Information - Apremilast is a small molecule inhibitor specifically targeting phosphodiesterase-4 (PDE4), which regulates intracellular inflammatory signaling pathways [1] - The drug effectively inhibits the release of pro-inflammatory factors and increases the production of anti-inflammatory factors, allowing for precise control of inflammatory responses [1] - Apremilast tablets are recognized for their rapid onset of action, clear efficacy, and high safety profile, making them a first-line systemic treatment option as per the "Chinese Psoriasis Diagnosis and Treatment Guidelines (2023 Edition)" [1]

Core Viewpoint - North China Pharmaceutical (000788.SZ) has received the drug registration certificate from the National Medical Products Administration for Apremilast tablets, indicating a significant advancement in its product portfolio for treating moderate to severe plaque psoriasis in adults [1] Group 1: Product Details - Apremilast is a small molecule inhibitor specifically targeting phosphodiesterase-4 (PDE4), which regulates intracellular inflammatory signaling pathways [1] - The drug effectively inhibits the release of pro-inflammatory factors and increases the production of anti-inflammatory factors, allowing for precise control of inflammatory responses [1] - Apremilast tablets are recognized for their rapid onset of action, clear efficacy, and high safety profile [1] Group 2: Clinical Guidelines - Apremilast has been included as a first-line systemic treatment option in the "Chinese Guidelines for the Diagnosis and Treatment of Psoriasis (2023 Edition)" for patients eligible for phototherapy or systemic therapy [1]